COVID-19 vaccines: authorised
Vaccines authorised in the European Union (EU) to prevent COVID-19, following evaluation by the European Medicines Agency (EMA).
EMA is not involved in advising on travel requirements in the EU, such as vaccination, quarantine or testing for travellers.
Decisions about which COVID-19 vaccines are included, for example, in the EU Digital COVID Certificate, are taken by the EU Member States. EMA is in charge of the scientific evaluation of vaccines for EU marketing authorisation. The acceptability criteria for travel purposes are broader and can include, for example, World Health Organization (WHO) listed vaccines that have not necessarily undergone the EMA process of authorisation.
Official information on this topic is available in all EU languages at:
The following vaccines can be used in the EU to prevent COVID-19:
|Vaccine||Marketing authorisation holder||Key milestones||More information|
|Vaxzevria (previously COVID-19 Vaccine AstraZeneca)||AstraZeneca AB|
Conditional marketing authorisation issued: 29/01/2021
Annual renewal issued: 09/11/2021
|Moderna Biotech Spain S.L.|
Conditional marketing authorisation issued: 06/01/2021
Annual renewal issued: 04/10/2021
Comirnaty (developed by BioNTech and Pfizer)
|BioNTech Manufacturing GmbH|
Conditional marketing authorisation issued: 21/12/2020
Annual renewal issued: 03/11/2021
|Janssen-Cilag International NV|
Conditional marketing authorisation issued: 11/03/2021
Annual renewal application: under evaluation
For more information on how EMA evaluated these vaccines, see:
EMA monitors the safety of COVID-19 vaccines authorised in the EU extremely carefully. This enables the detection of any rare side effects that may emerge once many millions of people are vaccinated.
Safety updates on each COVID-19 vaccine are available:
EMA is actively involved in approving new manufacturing sites to increase manufacturing capacity and supply of COVID-19 vaccines in the EU: